Caribou Biosciences reports Q3 EPS (30c) vs. (38c) last year

Reports Q3 revenue $2.2M vs. $2.0M last year. Cash, cash equivalents, and marketable securities were $159.2M as of September 30. Caribou expects its cash runway will be sufficient to fund its current operating plan into 2H 2027. “We were thrilled to recently share positive clinical data from both our off-the-shelf CAR-T cell therapy programs, vispa-cel for second-line large B cell lymphoma and CB-011 for relapsed or refractory multiple myeloma. These results represent a defining moment for our company and the field of allogeneic CAR-T cell therapy,” said Rachel Haurwitz, Caribou’s president and CEO. “As we advance both programs, we are committed to delivering on the promise of off-the-shelf cell therapies – offering rapid treatment, scalable manufacturing, and the possibility of broad patient access.” The company recently shared positive clinical data from its ANTLER phase 1 trial for vispa-cel and from the dose escalation portion of the CaMMouflage phase 1 trial for CB-011.